The situation surrounding Valeant Pharmaceuticals has transformed the company into a "great mystery," CNBC's Jim Cramer said Monday.
"The numbers are all over the map. No one knows what the cash flow is; no one knows what the company is doing," he said on "Squawk on the Street." "These are the things [you find] with a private, family company and there's a rivalry. This is a public company. This is quite frankly a travesty."
Cramer made his remarks after Valeant announced CEO J. Michael Pearson would be leaving the company, as the U.S. government investigates its business and accounting practices.